We have reported a decrease in the number of arcuate nucleus (ARC)-immunoreactive β-endorphin neurons in old (24 months) female C57BL/6J mice versus young (5 months) mice. Here, we have tested by immunocytochemistry whether age-related changes in β-endorphin neuron numbers are selective for β-endorphin neurons which do or do not contain estrogen receptors (E2R). We also compared β-endorphin neuron number in mice with short- (S) and long-duration (L) ovariectomy (OVX), since the latter may protect against neuroendocrine aging. Mice were studied at 5 (young), 12 (middle-aged), or 23-24 months (old). When the mean number of neurons per tissue section (15 sections per animal) was examined, there were no significant differences between young and middle-aged S-OVX females for either β-endorphin, E2R, or β-endorphin/ E2R neuron number. However, there were significant decreases in β-endorphin-containing neurons in the oldest age group versus young females (young S-OVX: 74.4 ± 11 (±SD) immunopositive neurons per tissue section, n = 10 mice; young L-OVX: 61.6 ± 6.9, n = 6; old S-OVX: 45.7 ± 9.9, n = 7; and old L-OVX: 37.5 ± 7.3, n = 7). There were also decreases in β-endorphin neurons which contained E2R in the oldest animals (young S-OVX: 16.6 ± 6.4; young L-OVX: 13.7 ± 1.3; old S-OVX: 9.2 ± 1.8; L-OVX: 6.0 ± 1.5) (p < 0.05 ANOVA). Both age (p < 0.001, two-way ANOVA) and ovarian status (p < 0.05) independently affected neuron number for both the β-endorphin and β-endorphin E2R populations versus young mice. We tested whether the observed age and/or ovarian-related decreases were proportionally greater in the subpopulation of β-endorphin neurons which contained E2R compared to the total β-endorphin neuron population. In the oldest age group, there was no significant difference in the decrease with age in the population of β-endorphin neurons which contained E2R and the total β-endorphin population (p = 0.208). When we examined the E2R neuron population as compared to the β-endorphin neuron populations, age-related decreases in the β-endorphin neuronal population tended to be greater than the decreases seen in the E2R neuron population (p = 0.054 repeated measures ANOVA). The tyrosine hydroxylase (TH) neuron population was studied to test whether there were changes in another ARC neuron population. There was no age-related change in either TH neuron number (young S-OVX: 35.8 ± 6.2, n = 4; middle-aged S-OVX: 33.1 ± 2.8, n = 4; old S-OVX: 33.4 ± 3.4, n = 4) or in the number of TH neurons which contained E2R (young S-OVX: 7.6 ± 1.0; middle-aged S-OVX: 7.2 ± 0.8; old S-OVX: 6.9 ± 1.2). These data demonstrate that ARC β-endorphin-containing perikarya are sensitive to alterations associated both with age and ovarian status; these effects are independent of one another. Our findings fail to support the hypothesis that L-OVX has a protective effect on hypothalamic neurons in older females. The subpopulation of β-endorphin neurons that contain E2R are not affected to any greater degree by age or ovarian status than the β-endorphin neuron population as a whole in the old animal.

Keywords:
Opiate peptides, Catecholamines, Aging, Immunocytochemistry, Mouse, Sex steroid Receptors, Arcuate nucleus
This content is only available via PDF.
© 1995 S. Karger AG, Basel
1995
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.